NIH-funded research R01 grant

Testing a new treatment to improve heart health in patients starting hemodialysis

Official title: Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Funded at Brigham and Women's Hospital · NIH-10771276 · Data updated 2026-11-12

This study is looking at whether a combination of two heart medications, sacubitril and valsartan, can help improve heart health and protect kidney function in people who are just starting hemodialysis for advanced kidney failure.

More Hemodialysis research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBrigham and Women's Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startApril 1, 2022
Project endJanuary 31, 2026
Funding year2024
Award (this year)$343,680
NIH project number5R01DK129749-03
Project IDNIH-10771276 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients who are initiating hemodialysis due to advanced kidney failure and have cardiovascular concerns.

Less likely to help

Patients who are not starting hemodialysis or those without cardiovascular issues may not benefit from this research.

What this research studies

This research investigates the effects of a combination therapy using sacubitril and valsartan on patients who are beginning hemodialysis due to advanced kidney failure. The study aims to determine if this treatment can improve heart health and preserve kidney function in these patients, who are at high risk for cardiovascular issues. Participants will be randomly assigned to receive either the treatment or a placebo, and their heart and kidney health will be monitored over time. The goal is to find a safer and more effective way to manage the health of patients starting hemodialysis.

Why it matters

Potential benefit: If successful, this research could lead to improved heart health and better kidney function for patients starting hemodialysis.

How similar studies have gone: Previous studies have shown that similar therapies can improve cardiovascular outcomes in other patient populations, suggesting potential for success in this group.

Where this research is happening

  • Brigham and Women's Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Mccausland, Finnian R — Brigham and Women's Hospital
  • Study coordinator: Mccausland, Finnian R

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.